Showing 81-90 of 108 results for "".
- Data Support Benefits of Natural Skincare: Burt's Beeshttps://modernaesthetics.com/news/data-support-benefits-of-natural-skincare-burts-bees/2472826/Products and ingredients in the Burt’s Bees natural skincare line provide documented benefits, according to studies presented at the second annual Integrative Dermatology Symposium (IDS) in San Diego this month. Among the findings is evidenc
- Evolus: Jeuveau FDA Cleared for Aesthetic Injectionhttps://modernaesthetics.com/news/evolus-jeuveau-fda-cleared-for-aesthetic-injection/2471954/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- Bonti's Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://modernaesthetics.com/news/bontis-gateway-neuromodulator-performs-well-in-pase-2a-for-glabellar-lines/2472208/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serot
- Johnson & Johnson MedTech Launches Larger-Sized Breast Implants for Post-Mastectomy Reconstructionhttps://modernaesthetics.com/news/johnson-johnson-medtech-launches-larger-sized-breast-implants-for-post-mastectomy-reconstruction/2475365/Johnson & Johnson MedTech has announced the U.S. launch of MENTORTM Memory GelTM Enhanced Breast Implants, a new line of breast implants specifically developed for women undergoing primary or revision reconstruction after mastectomy. The implants, which received FDA appr
- Dr. Jason Bloom Shares Latest Innovations from Korean Skincare on Philadelphia Newscasthttps://modernaesthetics.com/news/dr-jason-bloom-shares-latest-skincare-innovations-from-korean-skincare/2473702/Korean skincare, also known as K-Beauty, has become increasingly popular in the United States as Americans look to achieve “glass” skin. Social media, particularly TikTok, has played a large role in promoting K-Beauty lines and products. Jason Bloom, MD, is the founder
- New Data Demonstrates Long-Term Safety, Efficacy of Galderma’s RelabotulinumtoxinAhttps://modernaesthetics.com/news/new-data-demonstrates-long-term-safety-efficacy-of-galdermas-relabotulinumtoxina/2473698/Galderma presented new phase III data from the READY-4 clinical trial at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting last week. The data demonstrates the long-term safety of RelabotulinumtoxinA (RelfydessTM) for frown lines and crow’s feet after repea
- Cetaphil Launches Rebrand with Debut of ‘For Everyone’s Sensitive Skin’ Campaignhttps://modernaesthetics.com/news/cetaphil-launches-rebrand-with-debut-of-for-everyones-sensitive-skin-campaign/2473689/A popular skincare line debuts “For Everyone’s Sensitive Skin” campaign as part of a rebrand. Cetaphil announced a complete brand “restage,” in a press release earlier this week. The brand is revamping its 77-year-old image with a bold, refreshed visual upgrade. 
- Epicutis® Launches Arctigenin Brightening Treatmenthttps://modernaesthetics.com/news/epicutis-launches-arctigenin-brightening-treatment/2473684/The newest addition to Epicutis’s science-based professional skincare line, which the company says treats skin health and not age, is the Arctigenin Brightening Treatment—a clean, clinically proven skin brightening treatment that Epicutis says dethrones Vitamin C as the reigning brigh
- Allergan Reports Positive Phase 3 Data for New Short-acting Neurotoxinhttps://modernaesthetics.com/news/allergans-trenibotulinumtoxine-bonte-smoothes-glabellar-lines-quickly/2473513/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- RelabotulinumtoxinA Update from Galdermahttps://modernaesthetics.com/news/relabotulinumtoxina-update-from-galderma/2473504/The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Galderma related to its pending Biologics License Application (BLA) for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity